Identification of a new missense mutation in MyBP-C associated with hypertrophic cardiomyopathy

Area of Science:

• Cardiovascular Genetics
• Molecular Cardiology
• Genetic Disease

Background:

• Hypertrophic cardiomyopathy (HCM) is a primary cardiac condition characterized by myocardial hypertrophy.
• Genetic defects in sarcomeric protein genes, including cardiac myosin binding protein C (MyBP-C), are primary causes of HCM.
• Previous studies identified splice site and duplication mutations in MyBP-C associated with HCM.

Observation:

• Mutation screening of a South African HCM population identified a novel missense mutation, Arg654His, in the MyBP-C gene.
• This mutation was present in a proband and three adult children, but only the proband exhibited significant disease.
• The Arg654His mutation is located outside the myosin and titin binding domains of MyBP-C.

Findings:

• This study reports the first disease-associated missense mutation in MyBP-C that does not involve the myosin or titin binding domains.
• The Arg654His mutation demonstrates variable expressivity within a family, suggesting other genetic or environmental factors influence HCM phenotype.
• The identification of this novel mutation expands the spectrum of MyBP-C mutations linked to hypertrophic cardiomyopathy.

Implications:

• This finding contributes to understanding the genetic basis of hypertrophic cardiomyopathy and the role of MyBP-C.
• Further research is needed to elucidate the functional consequences of the Arg654His mutation and its impact on cardiac function.
• The variable expressivity highlights the complexity of HCM pathogenesis and the need for personalized risk assessment.